These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Kilic N, Balkan E, Akgoz S, Sen N, Dogruyol H. Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131 [Abstract] [Full Text] [Related]
10. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. Perfetto EM, Subedi P, Jumadilova Z. Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388 [Abstract] [Full Text] [Related]
13. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Takei M, Homma Y, JAPANESE TOLTERODINE STUDY GROUP. Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744 [Abstract] [Full Text] [Related]
14. Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children. Ayan S, Kaya K, Topsakal K, Kilicarslan H, Gokce G, Gultekin Y. BJU Int; 2005 Aug; 96(3):411-4. PubMed ID: 16042740 [Abstract] [Full Text] [Related]
15. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder? Hartnett NM, Saver BG. J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700 [No Abstract] [Full Text] [Related]
16. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. Nijman RJ, Borgstein NG, Ellsworth P, Djurhuus JC. J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796 [Abstract] [Full Text] [Related]